These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27479177)

  • 1. A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.
    Verstovsek S; Talpaz M; Ritchie E; Wadleigh M; Odenike O; Jamieson C; Stein B; Uno T; Mesa RA
    Leukemia; 2017 Feb; 31(2):393-402. PubMed ID: 27479177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
    Gupta V; Mesa RA; Deininger MW; Rivera CE; Sirhan S; Brachmann CB; Collins H; Kawashima J; Xin Y; Verstovsek S
    Haematologica; 2017 Jan; 102(1):94-102. PubMed ID: 27634203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 study of the Janus kinase 2 (JAK2)
    Verstovsek S; Mesa RA; Salama ME; Li L; Pitou C; Nunes FP; Price GL; Giles JL; D'Souza DN; Walgren RA; Prchal JT
    Leuk Res; 2017 Oct; 61():89-95. PubMed ID: 28934680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
    Verstovsek S; Kantarjian H; Mesa RA; Pardanani AD; Cortes-Franco J; Thomas DA; Estrov Z; Fridman JS; Bradley EC; Erickson-Viitanen S; Vaddi K; Levy R; Tefferi A
    N Engl J Med; 2010 Sep; 363(12):1117-27. PubMed ID: 20843246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
    Pardanani A; Gotlib JR; Jamieson C; Cortes JE; Talpaz M; Stone RM; Silverman MH; Gilliland DG; Shorr J; Tefferi A
    J Clin Oncol; 2011 Mar; 29(7):789-96. PubMed ID: 21220608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
    Mascarenhas JO; Talpaz M; Gupta V; Foltz LM; Savona MR; Paquette R; Turner AR; Coughlin P; Winton E; Burn TC; O'Neill P; Clark J; Hunter D; Assad A; Hoffman R; Verstovsek S
    Haematologica; 2017 Feb; 102(2):327-335. PubMed ID: 27789678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
    Verstovsek S; Odenike O; Singer JW; Granston T; Al-Fayoumi S; Deeg HJ
    J Hematol Oncol; 2016 Dec; 9(1):137. PubMed ID: 27931243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pacritinib to treat myelofibrosis patients with thrombocytopenia.
    Tremblay D; Mascarenhas J
    Expert Rev Hematol; 2018 Sep; 11(9):707-714. PubMed ID: 30001163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
    Meyer SC
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
    DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
    Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
    Winton EF; Kota V
    Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis.
    Vannucchi AM
    Leuk Res; 2009 Dec; 33(12):1581-3. PubMed ID: 19573914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
    Al-Ali HK; Griesshammer M; le Coutre P; Waller CF; Liberati AM; Schafhausen P; Tavares R; Giraldo P; Foltz L; Raanani P; Gupta V; Tannir B; Ronco JP; Ghosh J; Martino B; Vannucchi AM
    Haematologica; 2016 Sep; 101(9):1065-73. PubMed ID: 27247324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothesis: how do JAK2-inhibitors work in myelofibrosis.
    Mesa R; Gale RP
    Leuk Res; 2009 Sep; 33(9):1156-7. PubMed ID: 19450878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
    Pardanani A; Harrison C; Cortes JE; Cervantes F; Mesa RA; Milligan D; Masszi T; Mishchenko E; Jourdan E; Vannucchi AM; Drummond MW; Jurgutis M; Kuliczkowski K; Gheorghita E; Passamonti F; Neumann F; Patki A; Gao G; Tefferi A
    JAMA Oncol; 2015 Aug; 1(5):643-51. PubMed ID: 26181658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis.
    Pardanani A; Tefferi A; Jamieson C; Gabrail NY; Lebedinsky C; Gao G; Liu F; Xu C; Cao H; Talpaz M
    Blood Cancer J; 2015 Aug; 5(8):e335. PubMed ID: 26252788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis.
    Jamieson C; Hasserjian R; Gotlib J; Cortes J; Stone R; Talpaz M; Thiele J; Rodig S; Pozdnyakova O
    J Transl Med; 2015 Sep; 13():294. PubMed ID: 26357842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.
    Jain T; Mesa R
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1101-1108. PubMed ID: 27598824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.